

# MiCAN

Technologies

## Evaluation and research in a common laboratory with Kyoto University

Our headquarters and research laboratory are located in Kyoto-University Katsura Venture Plaza, where Kyoto University nurtures the creation of new businesses utilizing new ideas/technologies and intellectual properties.

## OUR MISSION

**We contribute to the health of people throughout the world  
through provision of special blood cells  
produced using regenerative medicine technology.**

We produce and provide homogeneous and high precision human blood cells in the required quantity to drastically streamline the research of infectious diseases and evaluation of efficacy and safety of drugs and functional materials.

We also sell evaluation kits and offer various contract evaluation services.

## COMPANY PROFILE

**Name of company :** MiCAN Technologies, Inc.

**Address :** Kyoto-University Katsura Venture Plaza, 1-36, Goryo-ohara,  
Kyoto Nishikyo-ku, Kyoto 615-8245, Japan  
TEL : +81-75-381-3008

**Representative :** Kazuo Miyazaki, Chief Executive Officer

**Established :** July 2016


**Capital :** ¥80,095,003

**Business lineup :**

- Provision (sales) of blood cell-like cells for research using regenerative medicine technologies
- Evaluation service for pharmaceutical development (contract service) using the above-stated blood cell-like cells
- Contract service of various tests using the above-stated blood cell-like cells based on alternative methods to animal testing

# HISTORY

- 2015 ◆ Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry
- July 2016 ◆ Foundation (Chuo-ku, Tokyo)
- November 2016 ◆ Awarded a grand prize of GLOBIS Venture Challenge
- October 2017 ◆ Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent application
- December 2017 ◆ Started development of myeloid cells for research of viruses (Mylc cells, second product)
- February 2018 ◆ Established a research and development base at Kyoto-University Katsura Venture Plaza
- July 2018 ◆ Started release of red blood-like cells (prototype product of Mpv cells)
- August 2018 ◆ Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University
- September 2018 ◆ Transferred the Headquarters to Kyoto-University Katsura Venture Plaza
- November 2018 ◆ Adopted for the Economic Gardening Support Grant supported by Kyoto Industrial Support Organization 21
- December 2018 ◆ Certified as Management of Wisdom by the Kyoto Chamber of Commerce and Industry
- March 2019 ◆ Expanded the Headquarters and Laboratory
- April 2019 ◆ Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.
- July 2019 ◆ Started release of myeloid cells for research of viruses (prototype product)
- August 2019 ◆ Raised ¥127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)
- November 2019 ◆ Awarded a grand prize and Kansai Mirai Bank award of the first round of Osaka Tech Planter.
- April 2020 ◆ Started collaborative research on corona virus using Mylc cells with Osaka University
- June 2020 ◆ Selected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMED



# COMMITMENT

When I was working in India in my previous career, a number of coworkers succumbed to infectious diseases such as malaria and dengue. Vivax malaria, for which rapid development of new drugs is desired. Dengue fever, for which people are waiting for the development of a vaccine. All research and development of drugs for infectious diseases mediated by blood require a huge number of specific blood cells, and the difficulty in procuring them was the largest cause of the delay in the development of drugs and vaccines. Thus, I made up my mind to produce and provide the specific blood cells required in large quantity at low price using regenerative medicine technology, a cutting-edge technology of Japan.

After I returned to Japan, my business plan was accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry in 2015. Then, my business went into full-scale operation and I established my company in 2016. After that, I have received various business support from local governments, associations, and investment institutions and won awards from multiple organizations, and I have been energetically developing blood cell-like cells and providing them to the world with like-minded colleagues and employees.

In 2020, the world is in the midst of the COVID-19 pandemic. In this situation, I sincerely hope that MiCAN's blood cells can help accelerate the development of new drugs and vaccines.

**Kazuo Miyazaki,**  
Chief Executive Officer

